就生物资产、商誉审计，江苏证监局总结了主要问题、提出监管要求！

Core Viewpoint - The article emphasizes the high audit risks associated with biological assets and goodwill, highlighting the need for enhanced regulatory measures to improve audit quality and the reliability of financial information [1][6]. Group 1: Biological Asset Audit - Biological assets are characterized by strong life activity, rapid dynamic changes in quantity and value, and high natural risks, making them a challenging area for audit verification [1][6]. - Key issues identified in the audit of biological assets include inadequate risk assessment procedures, insufficient control testing, and ineffective substantive procedures [2][7]. - Specific problems include failure to identify significant misstatement risks related to biological assets, lack of control testing on critical lifecycle processes, and inadequate execution of monitoring procedures [8][9][10]. - Regulatory requirements emphasize the need for auditors to understand the specific types of biological assets and their operational models, implement control tests at key lifecycle points, and develop comprehensive monitoring plans [12][13][14]. Group 2: Goodwill Audit - Goodwill is a high-risk area for financial fraud, with significant management judgment involved in its initial recognition and subsequent measurement [18]. - Major issues in goodwill audits include inadequate verification of acquisition pricing, insufficient scrutiny of the commercial substance of transactions, and failure to properly assess impairment testing processes [19][20]. - Auditors are urged to thoroughly review acquisition agreements, valuation reports, and the rationale behind pricing to prevent potential profit manipulation through excessive premiums [23][24]. - Regulatory measures call for auditors to maintain professional skepticism, evaluate the appropriateness of goodwill allocation, and ensure the reliability of management's estimates and assumptions during impairment testing [25][26][28].